Business
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
PLYMOUTH MEETING, Pa., January 12, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenue for Q4 and full year 2025 of approximately $243 million and $868 million, respectively. The company continues to build on six consecutive years of revenue growth. On track to extend the pitolisant franchise, Harmony fortifies its profile as a profitable, self-funding biotech company with a robust, late-stage pipeline and strong long-term gro
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4113,"height":1051,"url":"https://media.zenfs.com/en/business-wire.com/12821c2dc5af32237b4899ff8145d376"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v0T0vhwahSJk26gbCMNsnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/12821c2dc5af32237b4899ff8145d376","width":960,"height":245},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/qAUk2baO1eMXsOOTBIAXfQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/12821c2dc5af32237b4899ff8145d376","width":1200,"height":307}},"lazy":false},{"type":"text","content":"WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy","length":154,"tagName":"p","attribs":{}},{"type":"text","content":"On Track to Extend the Pitolisant Franchise into the 2040s With Next-Gen Pitolisant Formulations","length":96,"tagName":"p","attribs":{}},{"type":"text","content":"Potential Best-In-Class Orexin-2 Agonist (BP1.15205) Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026 ","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"Robust Late-Stage Pipeline with Five Ongoing Phase 3 Registrational Clinical Trials in Five Distinct CNS Indications","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"PLYMOUTH MEETING, Pa., January 12, 2026--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenue for Q4 and full year 2025 of approximately $243 million and $868 million, respectively. The company continues to build on six consecutive years of revenue growth. On track to extend the pitolisant franchise, Harmony fortifies its profile as a profitable, self-funding biotech company with a robust, late-stage pipeline and strong long-term growth potential. Harmony will highlight its commercial performance and pipeline advancements at its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA.","length":763,"tagName":"p"},{"type":"text","content":""With WAKIX on track to achieve revenue of over $...